Svezia - svedese - Läkemedelsverket (Medical Products Agency)

bluefish pharmaceuticals ab - ibandronatnatriummonohydrat - filmdragerad tablett - 50 mg - laktosmonohydrat hjälpämne; ibandronatnatriummonohydrat 56,26 mg aktiv substans - ibandronat

Unione Europea - svedese - EMA (European Medicines Agency)

sandoz gmbh - ibandronsyra - breast neoplasms; neoplasm metastasis; fractures, bone - läkemedel för behandling av skelettsjukdomar, bisfosfonater - ibandronsyra sandoz är indicerat för förebyggande av skeletthändelser (patologiska frakturer, benkomplikationer som kräver strålbehandling eller operation) hos patienter med bröstcancer och benmetastaser.

Unione Europea - svedese - EMA (European Medicines Agency)

teva pharma b.v. - ibandronsyra - breast neoplasms; neoplasm metastasis; fractures, bone; osteoporosis, postmenopausal - läkemedel för behandling av bensjukdomar - ibandronic acid 50mgibandronic acid teva är indicerat för prevention av skelett händelser (patologiska frakturer, ben komplikationer som kräver strålning eller operation) hos patienter med bröstcancer och benmetastaser. ibandronic acid 150mgtreatment of osteoporosis in postmenopausal women at increased risk of fracture. en minskning i risken för vertebrala frakturer har visats effekt på brott på lårbenshalsen har inte fastställts.

Unione Europea - svedese - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Unione Europea - svedese - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiska medel för suidae - grisar (för gödning) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Svezia - svedese - Läkemedelsverket (Medical Products Agency)

angelini pharma s.p.a. - fentanylcitrat - resoriblett, sublingual - 133 mikrogram - fentanylcitrat 210 mikrog aktiv substans; propylenglykol hjälpämne - fentanyl

Svezia - svedese - Läkemedelsverket (Medical Products Agency)

grunenthal sweden ab - fentanylcitrat - resoriblett, sublingual - 133 mikrogram - fentanylcitrat 210 mikrog aktiv substans; propylenglykol hjälpämne - fentanyl

Svezia - svedese - Läkemedelsverket (Medical Products Agency)

grunenthal sweden ab - fentanylcitrat - resoriblett, sublingual - 133 mikrogram - fentanylcitrat 210 mikrog aktiv substans; propylenglykol hjälpämne - fentanyl

Svezia - svedese - Läkemedelsverket (Medical Products Agency)

ethypharm sa - fentanylcitrat - resoriblett, sublingual - 133 mikrogram - propylenglykol hjälpämne; fentanylcitrat 210 mikrog aktiv substans - fentanyl

Svezia - svedese - Läkemedelsverket (Medical Products Agency)

angelini pharma s.p.a. - fentanylcitrat - resoriblett, sublingual - 267 mikrogram - fentanylcitrat 420 mikrog aktiv substans; propylenglykol hjälpämne - fentanyl